Journal
VACCINE
Volume 41, Issue 2, Pages 285-289Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2022.11.057
Keywords
Human papillomavirus; Vaccine effectiveness; Observational study
Categories
Ask authors/readers for more resources
The long-term effectiveness of three-dose HPV16/18 vaccination among Dutch women who were eligible for vaccination during a catch-up campaign was evaluated. The vaccine showed high effectiveness of 95.8% against persistent infections with HPV16/18 and 64.6% against cross protective type persistent infections (HPV31/33/45). There was no evidence of waning of protection over time, indicating promising long-term protection and future clinical impact.
The current study describes the long-term effectiveness of three-dose HPV16/18 vaccination among Dutch women who were eligible for vaccination during a catch-up campaign and were followed in an observational cohort study. Ten years post vaccination, vaccine effectiveness (VE) was estimated using generalized estimating equation models. VE against persistent infections with vaccine type infections (HPV16/18) was high at 95.8%. For cross protective type persistent infections (HPV31/33/45) this was 64.6%. There were no indications of waning of protection over time. This indicates solid long-term protection is provided by the vaccine and is promising with regard to the future clinical impact. (c) 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available